vs
Side-by-side financial comparison of NORTECH SYSTEMS INC (NSYS) and RHYTHM PHARMACEUTICALS, INC. (RYTM). Click either name above to swap in a different company.
RHYTHM PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($57.3M vs $30.3M, roughly 1.9× NORTECH SYSTEMS INC). NORTECH SYSTEMS INC runs the higher net margin — 3.0% vs -83.0%, a 85.9% gap on every dollar of revenue. On growth, RHYTHM PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (36.9% vs 5.9%). Over the past eight quarters, RHYTHM PHARMACEUTICALS, INC.'s revenue compounded faster (48.5% CAGR vs -5.9%).
Nortech Systems Inc is a global electronics manufacturing services provider. It delivers end-to-end solutions covering product design, prototyping, full-scale production, and supply chain management for clients operating in medical technology, industrial automation, aerospace and defense, and transportation sectors. It specializes in high-reliability, regulatory-compliant electronic components and assemblies tailored to strict industry standards.
Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.
NSYS vs RYTM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $30.3M | $57.3M |
| Net Profit | $897.0K | $-47.5M |
| Gross Margin | 16.7% | 91.6% |
| Operating Margin | 3.0% | -82.2% |
| Net Margin | 3.0% | -83.0% |
| Revenue YoY | 5.9% | 36.9% |
| Net Profit YoY | 160.7% | -9.6% |
| EPS (diluted) | $0.32 | $-0.73 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $30.3M | $57.3M | ||
| Q3 25 | $30.5M | $51.3M | ||
| Q2 25 | $30.7M | $48.5M | ||
| Q1 25 | $26.9M | $32.7M | ||
| Q4 24 | $28.6M | $41.8M | ||
| Q3 24 | $31.4M | $33.3M | ||
| Q2 24 | $33.9M | $29.1M | ||
| Q1 24 | $34.2M | $26.0M |
| Q4 25 | $897.0K | $-47.5M | ||
| Q3 25 | $-146.0K | $-52.9M | ||
| Q2 25 | $313.0K | $-46.6M | ||
| Q1 25 | $-1.3M | $-49.5M | ||
| Q4 24 | $-1.5M | $-43.3M | ||
| Q3 24 | $-739.0K | $-43.6M | ||
| Q2 24 | $157.0K | $-32.3M | ||
| Q1 24 | $765.0K | $-141.4M |
| Q4 25 | 16.7% | 91.6% | ||
| Q3 25 | 16.5% | 89.3% | ||
| Q2 25 | 15.8% | 88.6% | ||
| Q1 25 | 11.4% | 88.8% | ||
| Q4 24 | 9.9% | 90.9% | ||
| Q3 24 | 12.2% | 88.5% | ||
| Q2 24 | 13.6% | 89.9% | ||
| Q1 24 | 15.9% | 89.2% |
| Q4 25 | 3.0% | -82.2% | ||
| Q3 25 | 3.1% | -102.6% | ||
| Q2 25 | 2.4% | -93.4% | ||
| Q1 25 | -6.0% | -143.7% | ||
| Q4 24 | -4.3% | -98.6% | ||
| Q3 24 | -1.5% | -132.0% | ||
| Q2 24 | 1.0% | -139.2% | ||
| Q1 24 | 3.4% | -538.7% |
| Q4 25 | 3.0% | -83.0% | ||
| Q3 25 | -0.5% | -103.1% | ||
| Q2 25 | 1.0% | -96.1% | ||
| Q1 25 | -4.9% | -151.4% | ||
| Q4 24 | -5.2% | -103.6% | ||
| Q3 24 | -2.4% | -131.2% | ||
| Q2 24 | 0.5% | -110.9% | ||
| Q1 24 | 2.2% | -544.4% |
| Q4 25 | $0.32 | $-0.73 | ||
| Q3 25 | $-0.05 | $-0.82 | ||
| Q2 25 | $0.12 | $-0.75 | ||
| Q1 25 | $-0.48 | $-0.81 | ||
| Q4 24 | $-0.51 | $-0.71 | ||
| Q3 24 | $-0.27 | $-0.73 | ||
| Q2 24 | $0.05 | $-0.55 | ||
| Q1 24 | $0.26 | $-2.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.7M | $388.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $34.5M | $139.1M |
| Total Assets | $71.9M | $480.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.7M | $388.9M | ||
| Q3 25 | $1.3M | $416.1M | ||
| Q2 25 | $652.0K | $291.0M | ||
| Q1 25 | $1.2M | $314.5M | ||
| Q4 24 | $916.0K | $320.6M | ||
| Q3 24 | $1.2M | $298.4M | ||
| Q2 24 | $1.5M | $319.1M | ||
| Q1 24 | $4.0M | $201.2M |
| Q4 25 | $34.5M | $139.1M | ||
| Q3 25 | $33.4M | $148.8M | ||
| Q2 25 | $33.4M | $-11.9M | ||
| Q1 25 | $32.8M | $18.9M | ||
| Q4 24 | $34.0M | $21.7M | ||
| Q3 24 | $35.7M | $11.2M | ||
| Q2 24 | $36.1M | $39.3M | ||
| Q1 24 | $36.0M | $61.6M |
| Q4 25 | $71.9M | $480.2M | ||
| Q3 25 | $74.8M | $506.9M | ||
| Q2 25 | $74.8M | $372.7M | ||
| Q1 25 | $73.5M | $386.7M | ||
| Q4 24 | $72.4M | $392.3M | ||
| Q3 24 | $77.0M | $363.6M | ||
| Q2 24 | $76.3M | $381.8M | ||
| Q1 24 | $75.5M | $258.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $5.6M | $-25.4M |
| Free Cash FlowOCF − Capex | $5.5M | — |
| FCF MarginFCF / Revenue | 18.0% | — |
| Capex IntensityCapex / Revenue | 0.5% | — |
| Cash ConversionOCF / Net Profit | 6.25× | — |
| TTM Free Cash FlowTrailing 4 quarters | $2.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $5.6M | $-25.4M | ||
| Q3 25 | $-92.0K | $-26.6M | ||
| Q2 25 | $157.0K | $-23.3M | ||
| Q1 25 | $-2.9M | $-40.4M | ||
| Q4 24 | $793.0K | $-18.8M | ||
| Q3 24 | $-1.6M | $-25.2M | ||
| Q2 24 | $-4.3M | $-29.1M | ||
| Q1 24 | $2.8M | $-40.7M |
| Q4 25 | $5.5M | — | ||
| Q3 25 | $-242.0K | — | ||
| Q2 25 | $58.0K | — | ||
| Q1 25 | $-3.2M | — | ||
| Q4 24 | $503.0K | — | ||
| Q3 24 | $-1.6M | — | ||
| Q2 24 | $-4.6M | — | ||
| Q1 24 | $2.1M | — |
| Q4 25 | 18.0% | — | ||
| Q3 25 | -0.8% | — | ||
| Q2 25 | 0.2% | — | ||
| Q1 25 | -11.9% | — | ||
| Q4 24 | 1.8% | — | ||
| Q3 24 | -5.2% | — | ||
| Q2 24 | -13.5% | — | ||
| Q1 24 | 6.1% | — |
| Q4 25 | 0.5% | — | ||
| Q3 25 | 0.5% | — | ||
| Q2 25 | 0.3% | — | ||
| Q1 25 | 1.0% | — | ||
| Q4 24 | 1.0% | — | ||
| Q3 24 | 0.1% | — | ||
| Q2 24 | 0.8% | — | ||
| Q1 24 | 2.2% | — |
| Q4 25 | 6.25× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.50× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -27.30× | — | ||
| Q1 24 | 3.70× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NSYS
| Medical Imaging | $11.4M | 37% |
| Medical Device | $8.0M | 26% |
| Industrial | $7.3M | 24% |
| Aerospace And Defense | $3.7M | 12% |
RYTM
Segment breakdown not available.
